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Cerebral amyloid angiopathy (CAA), the accumulation of β-amyloid (Aβ) peptides in the walls
of cerebral blood vessels, is observed in the majority of Alzheimer’s disease (AD) brains
and is thought to be due to a failure of the aging brain to clear Aβ. Perivascular drainage
of Aβ along cerebrovascular basement membranes (CVBMs) is one of the mechanisms by
which Aβ is removed from the brain. CVBMs are specialized sheets of extracellular matrix
that provide structural and functional support for cerebral blood vessels. Changes in CVBM
composition and structure are observed in the aged and AD brain and may contribute to
the development and progression of CAA. This review summarizes the properties of the
CVBM, its role in mediating clearance of interstitial fluids and solutes from the brain, and
evidence supporting a role for CVBM in the etiology of CAA.
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ALZHEIMER’S DISEASE AND CEREBRAL AMYLOID
ANGIOPATHY
Alzheimer’s disease (AD) is a chronic progressive neurodegen-
erative disease, currently estimated to affect 35.2 million peo-
ple worldwide, making it the commonest form of dementia
(Alzheimer’s Disease International, 2014). Life expectancy after
diagnosis ranges from 4 to 6 years (Larson et al., 2004). The main
risk factor is age, with the chance of developing AD doubling every
5 years after the age of 65 years (Gao et al., 1998). Other non-
modifiable risk factors include mutations in genes encoding the
amyloid precursor protein (APP) and presenilin-1 and -2 in famil-
ial AD cases (Tanzi, 2012) and possession of the apolipoprotein
E (ApoE) ε4 allele in sporadic AD (Tanzi, 2012). Midlife hyper-
tension, diabetes, and hypercholesterolemia are modifiable risk
factors that increase the risk of developing AD in late life (Launer
et al., 2000; Shah et al., 2012).
Alzheimer’s disease is characterized clinically by a slow and
gradual deterioration in cognitive function as well as psychi-
atric symptoms and behavioral disturbances such as depression,
delusions, and agitation (Burns, 1992; Bird and Miller, 2007).
Neuropathologically, AD is associated with brain region-specific
neuronal loss and synaptic degeneration (Bondareff et al., 1982;
Whitehouse et al., 1982; Vogels et al., 1990; Aletrino et al., 1992),
which begin in the entorhinal cortex and advance to the hip-
pocampus and posterior temporal and parietal cortices (Begley
et al., 1990; Braak and Braak, 1991). The end result of this
degenerative neuronal loss is brain shrinkage and ventricular
enlargement.
Two classical pathological features of AD are the accumula-
tion of neurofibrillary tangles (NFTs) and senile plaques (Braak
and Braak, 1991; Alafuzoff et al., 2008). NFTs are formed
predominantly of ubiquitinated hyperphosphorylated tau (Esiri
et al., 2004). Tau is a microtubule-associated protein that is present
in mature neurons. In AD, tau becomes hyperphosphorylated and
aggregates into NFTs of paired helical filaments (Iqbal et al., 2010).
These aggregated bundles are seen pathologically as intraneuronal
tangles in dystrophic neurites surrounding senile plaques and in
the neuropil as neuropil threads (Braak et al., 1986; Grundke-Iqbal
et al., 1986). Senile plaques are formed predominantly of amyloidβ
(Aβ). Amyloidogenic Aβ is produced from the sequential cleavage
of APP by two proteases, β- and γ-secretase.
In addition to its deposition in the parenchyma, Aβ accumu-
lates in the walls of cerebral blood vessels as cerebral amyloid
angiopathy (CAA) (Miyakawa et al., 1982; Vinters, 1987; Weller
et al., 2008). CAA is observed in 30–40% of non-demented elderly
individuals and 60–95% of AD brains studied at autopsy (Vinters,
1987; Castano and Frangione, 1988; Haan et al., 1991; Jellinger,
2002). It affects predominantly leptomeningeal and cortical arter-
ies but also occurs in cerebral capillaries (Vinters, 1987; Gian-
nakopoulos et al., 1997; Roher et al., 2003). Unlike the parenchymal
senile plaques that are composed principally of Aβ42 (Dickson
et al., 1988), vascular Aβ deposits comprise predominantly Aβ40
(Suzuki et al., 1994). CAA is associated with capillary thinning
and vessel tortuosity, inhibition of angiogenesis, and the death of
pericytes, endothelial, and smooth muscle cells (Perlmutter et al.,
1994; Miao et al., 2005; Haglund et al., 2006; Tian et al., 2006;
Burger et al., 2009). Cerebral hypoperfusion, microhemorrhages,
and cognitive impairment have also been shown to be associated
with CAA severity (Natte et al., 2001; Pfeifer et al., 2002a,b; Shin
et al., 2007; Chung et al., 2009).
The origin of the vascular Aβ deposits has been contested
since the early twentieth century when it was first proposed
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that blood-borne Aβ was causing the phenomenon (Scholz,
1938). In the presiding half-century, other mechanisms were
suggested, including the production of Aβ by vascular smooth
muscle cells (VSMCs) (Wisniewski and Wegiel, 1994; Vinters
et al., 1996; Wisniewski et al., 1996). However, the dichotomy
between the specific localization of CAA to cerebral blood
vessels and the ubiquitous expression of VSMCs throughout
the body, suggested a brain-based origin of vascular Aβ. This
hypothesis was supported by findings that transgenic mice pro-
ducing mutant human Aβ only in the brain develop CAA
(Herzig et al., 2004, 2006).
Based in part on electron microscopy studies showing the
deposition of Aβ within the cerebrovascular basement membrane
(CVBM) of the arterial tunica media (Wisniewski and Wegiel,
1994), Weller et al. (1998) hypothesized that parenchymal Aβ is
normally cleared from the brain along CVBM and that CAA results
from the failure of this system in the aged brain.
This review will summarize the properties of the CVBM, its
role in mediating clearance of interstitial fluid (ISF) and solutes
from the brain, and evidence supporting a role for CVBM in the
etiology of CAA.
THE BASEMENT MEMBRANE OF THE BRAIN
Basement membranes (BMs) are specialized extracellular matri-
ces 50–100 nm in size when visualized by transmission electron
microscopy (TEM) that cover the basal aspect of all endothe-
lial and epithelial cells and surround fat, muscle, and Schwann
cells (Carlson et al., 1978; Yurchenco and Schittny, 1990; Weber,
1992; Timpl, 1996; Miner, 1999; Candiello et al., 2007; McKee
et al., 2009; Rasi et al., 2010) (Figure 1). They are formed from
a variety of intracellularly produced proteins that are secreted
into the surrounding extracellular matrix (ECM). BMs provide
structural support to tissues, separate cells from connective tis-
sue, and are important in modulating cellular signaling path-
ways (Yurchenco and Schittny, 1990; Timpl and Brown, 1996;
Kalluri, 2003). The majority of BMs contain the following pro-
teins; type IV collagen, laminins, nidogen, and the major heparan
sulfate proteoglycan (HSPG) perlecan (Timpl and Brown, 1996;
Halfter et al., 2013). Each of these core BM proteins has a sub-
set of isoforms, there are 6 isoforms of type IV collagen, 2
nidogen isoforms, 2 major HSPGs (perlecan and agrin), and
16 different isoforms of laminin (Sorokin, 2010). Variation in
the structural composition of the core BM proteins results in
protein heterogeneity. For example, collagen IV comprises six
distinct polypeptide α-chains [α1(IV)–α6(IV)], which assemble
with high specificity to form three distinct isoforms, α1α1α2,
α3α4α5, andα5α5α6 (Khoshnoodi et al., 2008). Laminins are com-
posed of α, β, and γ polypeptide chain (Miner and Yurchenco,
2004). Currently 5 distinct α chains, 3 distinct β chains, and
3 distinct γ chains have been characterized and they assem-
ble in various combinations to form 16 different laminin iso-
forms, which are classified as α1β1γ1, which is abbreviated
to 111, depending on which chains make up the final mole-
cule (Aumailley et al., 2005). Auxiliary BM proteins including,
type XV collagen, type XVIII collagen, agrin, osteonectin [also
known as secreted protein acidic and rich in cysteine (SPARC)
or BM protein 40 (BM40)], BM90, and fibulin contribute to the
FIGURE 1 | Micrograph of corticalWistar Kyoto rat capillary. The
cerebrovascular basement membrane is the electron dense area between
the six arrow heads. Lu, capillary lumen; Edc, endothelial cell; Ast,
astrocyte end foot. TEM, 50,000×, scale bar, 500 nm.
structural and functional diversity of the BM across different
tissues (Timpl, 1996).
In the brain, BM proteins are expressed in the ECM of the
parenchyma and within multiple layers of the cerebral blood
vessels. Collagen IV (Khoshnoodi et al., 2008), laminin (Hagg
et al., 1989; Hunter et al., 1992; Jucker et al., 1996a,b; Hallmann
et al., 2005), nidogen -1 and -2 (Bader et al., 2005), HSPGs per-
lecan (Noonan and Hassell, 1993), fibronectin (Caffo et al., 2008),
and agrin (Barber and Lieth, 1997), are the predominant BM
constituents of the brain. However, there are variations in the
composition of individual cerebral BMs, especially with regards
to laminin. For example, the BM of the glia limitans contains
both laminin α1 and α2 (Hallmann et al., 2005), whereas only
laminin α1 is expressed in the meningeal epithelium and the
astrocytic endothelium contains only laminin α2 (Hallmann et al.,
2005). The different protein composition within each cerebral BM
influences numerous cellular functions such as neural stem cell
differentiation and migration, axon formation, apoptosis, myeli-
nation, and glial scar formation (Perris, 1997; Goldbrunner et al.,
1999; Thyboll et al., 2002).
Cerebrovascular basement membranes play an important role
in blood vessel development and health, formation and main-
tenance of the blood–brain barrier (BBB) and migration of
peripheral cells including leukocytes into the brain (Sixt et al.,
2001; Zlokovic, 2008; Wu et al., 2009). Endothelial cells, astro-
cytes and smooth muscle cells (Zlokovic, 2008) all contribute
to the composition of the CVBM (Yousif et al., 2013) and this
also receives contributions from pericytes (Dohgu et al., 2005;
Bell et al., 2010) (Figure 2). The CVBM comprises collagen IV,
laminin, perlecan, and nidogen as well as several minor glyco-
proteins (Hallmann et al., 2005). There is, however, variation in
the expression of laminin isoforms within the CVBM of differ-
ent vessel types (Sorokin, 2010). At the capillary level, the BM
is fused between the endothelial cells and astrocyte end feet and
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FIGURE 2 | Composition of the neurovascular unit. (A) Diagram of
leptomeningeal artery. Viewed from the center: arterial lumen (red),
endothelial cell (blue), cerebrovascular basement membrane (light green),
vascular smooth muscle cells (orange) have a cerebrovascular basement
membrane running between them and are penetrated by nerve fibres
(yellow), pia mater (dark green), and astrocyte end foot (teal).
(B) Micrograph of C57BL/6 mouse cortical artery. Lu, lumen; Edc,
endothelial cell; Smc, vascular smooth muscle cell; CVBM, cerebrovascular
basement membrane; Pm, pia mater; sub, subarachnoid space. TEM,
25,000×, scale bar, 1000 nm, image credit : Matthew M. Sharp. (C) Diagram
of a cerebral capillary. Viewed from the center; capillary lumen (red),
endothelial cell (blue), cerebrovascular basement membrane (light green),
pericyte (purple), and astrocyte end foot (teal). (D) Micrograph of Wistar
Kyoto rat cerebral capillary. Lu, lumen; Edc, endothelial cell; Pct, pericyte;
CVBM, cerebrovascular basement membrane; Ast, astrocyte end foot.
TEM, 50,000×; scale bar, 500 nm.
contains laminin α2, α4, and α5 (Hallmann et al., 2005). Cere-
bral arterioles and arteries contain an endothelial BM (contain-
ing laminin α4 and/or α5), a BM that surrounds the VSMCs
within tunica media (containing laminin α1 and α2) and an
astrocytic BM (containing laminin α1 and α2) (Sixt et al., 2001).
Veins comprise an endothelial BM (containing laminin α4 and
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FIGURE 3 | Micrographs showing the continuity between the extracellular matrix and the cerebrovascular basement membrane. (A,B)Wistar Kyoto rat
cerebral capillary, TEM, 50,000× scale bar 500 nm. (C,D) Magnified insert highlighting continuity between the BM and extracellular matrix. The extracellular
matrix is the electron dense area between the two arrow heads in (C,D). Ast, astrocyte end foot; CVBM, cerebrovascular basement membrane.
a patchy distribution of laminin α5), a smooth muscle BM
(containing laminin α1 and α2), and an astrocytic BM (con-
taining laminin α2, α4, and α5) (Sixt et al., 2001; Yousif et al.,
2013).
PERIVASCULAR ELIMINATION PATHWAY OF ISF
The brain only accounts for around 2% of total body mass, but it is
responsible for approximately a quarter of the body’s total oxygen
and glucose consumption (Zlokovic, 2008). This metabolic out-
put produces large quantities of waste neurotoxins that must be
transported, along with other solutes, out of the brain for eventual
excretion from the body. Unlike peripheral organs that communi-
cate with the lymphatic system to remove ISF, the brain does not
have conventional lymphatics. Solutes that cannot be eliminated
across the BBB or into the CSF must therefore be removed via
alternative routes.
Transmission electron microscopy analyses indicate continuity
between the extracellular spaces of the brain and the endothelial
capillary BM (Figure 3), suggesting a putative pathway by which
parenchymal ISF may be cleared. Results from early drainage
studies found that large molecular weight compounds injected
into the brain parenchyma spread along perivascular spaces and
could be observed in the walls of leptomeningeal arteries and
in cervical lymph nodes (Szentistvanyi et al., 1984). Further,
the clearance of small and large molecules occurred at simi-
lar rates (Cserr et al., 1981), suggesting that movement of ISF
was dependent on bulk flow rather than diffusion, with an esti-
mated clearance rate of 0.15–0.29µL/min/g in the rat brain
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and 0.10–0.15µL/min/g in the rabbit (Szentistvanyi et al., 1984;
Abbott, 2004; Carare et al., 2008).
The role of the CVBM in the perivascular clearance of
parenchymal solutes was shown experimentally by Carare et al.,
who found that fluorescent tracers were localized to the BM
of both capillaries and arteries within 5 min of injection into
the deep gray matter (Carare et al., 2008). In arterial walls, the
tracers were specifically located in the BM of the tunica media,
but not in the endothelial BM or the outer most BM between
the arterial wall and brain parenchyma (Carare et al., 2008). At
3 h after injection, the tracer had cleared the CVBMs and trac-
ers were only visible within perivascular macrophages (Carare
et al., 2008). More recent studies using multiphoton imaging
have confirmed the drainage of intracerebrally injected tracers
along perivascular BMs (Arbel-Ornath et al., 2013). This path-
way appears specific to small solutes, as large molecules, includ-
ing immune complexes, Indian ink, and 20 nm fluorospheres are
unable to enter the CVBM (Zhang et al., 1992; Barua et al., 2012;
Teeling et al., 2012).
The motive force for the perivascular elimination pathway is
still unclear. It has been hypothesized that cerebral blood flow
plays a major role because clearance ceases immediately after car-
diac arrest (Carare et al., 2008). Mathematical models have also
provided insight into potential mechanisms by highlighting the
potential for reflection wave driven flow (Schley et al., 2006; Wang
and Olbricht, 2011). Each arterial pulsation is followed by a con-
trary (reflection) wave that passes along the vessel wall in the
opposite direction to blood flow, which matches the observed
pattern of distribution of solutes injected into the gray matter
(Schley et al., 2006; Wang and Olbricht, 2011). This reflection
wave could be aided by conformational changes in the CVBMs
occurring during constriction and relaxation of the vessel wall in
arteries (Carare et al., 2013) and of pericytes in capillaries. BM
proteins may also adopt a valve-like configuration to prevent the
ISF back flow (Schley et al., 2006).
ROLE OF CVBM AND PERIVASCULAR DRAINAGE IN CAA
Since the initial studies into perivascular elimination of solutes, it
has been shown that soluble Aβ follows the same route after injec-
tion (Figure 4) (Hawkes et al., 2011, 2012, 2013). The pattern of
distribution closely matches with that of human CAA, supporting
the hypothesis that CAA outlines the natural route of elimination
of cerebral Aβ. Multiple additional lines of evidence suggest an
important role for CVBMs in the clearance of Aβ and its failure
in CAA:
MORPHOLOGIC CHANGES IN THE CEREBROVASCULATURE AND CVBM
Thickening, splitting, duplication, and the presence of abnor-
mal inclusions in the CVBM have been reported in the brains
of aged animals and humans and to a greater degree in the AD
brain (Perlmutter, 1994; Kalaria, 1996; Farkas and Luiten, 2001;
Shimizu et al., 2009). Thickening of the CVBM in both rodents
and humans appears to be most predominant in brain areas that
are susceptible to AD and CAA pathology (Zarow et al., 1997;
Hawkes et al., 2013) and precedes CAA onset in TGF-β transgenic
mice (Wyss-Coray et al., 2000). Further, increasing age is associ-
ated with arterial rigidity, elongation, and tortuosity, as well as a
FIGURE 4 | Diagram depicting the perivascular elimination of solutes
along the cerebrovascular basement membrane of a cerebral capillary.
The arterial pulsatile wave driving blood flow into the brain (red arrows) is
followed by a refractory wave, which may drive the movement of interstitial
fluid (ISF) out of the brain along the cerebrovascular basement membrane
(green arrow). Conformational changes in cerebrovascular basement
membranes during the refractory wave may provide a valve-like mechanism
that promotes unidirectional flow of ISF. Viewed from the center: capillary
lumen (red), endothelial cell layer (blue), cerebrovascular basement
membrane (light green), pericyte (purple), and astrocyte end foot (teal) with
a section removed beyond dotted line.
reduction in the vascular content of smooth muscle (Dahl, 1976).
Such changes may diminish the force of arterial contraction and
thereby diminish the driving force for perivascular clearance of Aβ.
CHANGES IN THE BIOCHEMICAL COMPOSITION OF THE CVBM
Laminin, nidogens, and collagen IV inhibit the aggregation of
Aβ and destabilize pre-formed fibrils of Aβ in vitro, while HSPG
agrin and perlecan accelerate its aggregation (Aumailley and Krieg,
1996; Bronfman et al., 1996, 1998; Castillo et al., 1997; Cotman
et al., 2000; Kiuchi et al., 2002a,b). Decreased amounts of collagen
IV have been reported in small diameter vessels (<50µm) from
AD patients compared to aged-matched controls (Christov et al.,
2008). Conversely, the levels of HSPGs were increased in AD brains
(Berzin et al., 2000; Shimizu et al., 2009). Similar alterations have
also been observed in the levels of collagen IV, laminin, nidogen 2,
fibronectin, and perlecan in CAA-vulnerable brain regions of aged
mice (Hawkes et al., 2013). These data suggest a change in the BM
composition of the aged brain toward a pro-amyloidogenic envi-
ronment. In addition, mice expressing the human ApoE ε4 allele
show greater changes in CVBM expression over the lifecourse than
mice expressing human Apo ε3 allele, in association with disrupted
perivascular drainage of Aβ40 (Hawkes et al., 2012).
RELATIONSHIP BETWEEN PARENCHYMAL AND VASCULAR Aβ
Increased CAA severity has been noted in the brains of both
mice and humans following anti-Aβ immunotherapy in associ-
ation with decreased cerebral plaque load (Pfeifer et al., 2002b;
Wilcock et al., 2004; Patton et al., 2006; Boche et al., 2008). These
vascular Aβ deposits contained high levels of Aβ42, suggesting
that following immunization,parenchymal Aβbecame solubilized,
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drained along CVBMs, and became entrapped in the perivascular
drainage pathways.
Collectively, these findings indicate that alterations in the com-
position, level of expression, or morphology of CVBMs may dis-
turb perivascular drainage of Aβ from the parenchyma and initiate
the deposition of Aβ within the walls of the cerebral vasculature,
leading to a feed-forward mechanism of Aβ accumulation as CAA.
CONCLUSION
Increasing evidence supports a role for the cerebrovasculature in
the development of AD. Preventative strategies targeting cardio-
vascular risk factors have been shown to be effective in reducing
the incidence of AD (Guo et al., 1999; in’t Veld et al., 2001; Ohrui
et al., 2004; Khachaturian et al., 2006; Haag et al., 2009a,b; Sink
et al., 2009; Chuang et al., 2014), supporting the importance of
maintaining cerebral vascular health across the lifespan in the
prevention of disease. The CVBM plays an important role in
cerebrovascular health, including mediating the clearance of Aβ.
Therapeutic strategies targeted at improving and/or facilitating
perivascular drainage of Aβ along the CVBM of the elderly brain
may therefore represent a novel approach to the treatment of AD
and CAA.
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